Sionna Therapeutics' stock plummeted 92% following the failure of its cystic fibrosis drug in a mid-stage trial. The drug did not provide a meaningful additive impact when combined with Vertex's top-selling Trikafta, leading to a significant collapse in company shares.
Vertex Pharmaceuticals has entered into a partnership with AbCellera, paying $28 million upfront for access to its T-cell engager platform. This collaboration aims to develop treatments for autoimmune conditions and adds to Vertex's efforts to diversify beyond its cystic fibrosis medicines.
AbCellera has announced a collaboration with Vertex to discover multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. This partnership adds to Vertex's efforts to diversify its portfolio, which has been heavily reliant on cystic fibrosis medicines.
AbCellera has announced a collaboration with Vertex to discover multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. This partnership adds to a series of collaborations focused on innovative T-cell engagers, providing Vertex an opportunity to diversify its portfolio beyond its reliance on cystic fibrosis treatments.
AbCellera has announced a collaboration with Vertex to discover multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. This partnership adds to Vertex's ongoing efforts to diversify its portfolio, which has been heavily focused on cystic fibrosis medications.
Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket